The estimated Net Worth of Paribas Securities Corp Bnp is at least $702 Thousand dollars as of 6 September 2023. Paribas Bnp owns over 20,800 units of ADiTx Therapeutics stock worth over $10,948 and over the last few years Paribas sold ADTX stock worth over $691,184.
Paribas has made over 1 trades of the ADiTx Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently Paribas sold 20,800 units of ADTX stock worth $691,184 on 6 September 2023.
The largest trade Paribas's ever made was selling 20,800 units of ADiTx Therapeutics stock on 6 September 2023 worth over $691,184. On average, Paribas trades about 20,800 units every 0 days since 2023. As of 6 September 2023 Paribas still owns at least 22,342 units of ADiTx Therapeutics stock.
You can see the complete history of Paribas Bnp stock trades at the bottom of the page.
Paribas's mailing address filed with the SEC is Seventh Avenue, Calverton, Town of Riverhead, Suffolk County, New York, 11933, United States.
Over the last 4 years, insiders at ADiTx Therapeutics have traded over $691,184 worth of ADiTx Therapeutics stock and bought 24,613 units worth $89,662 . The most active insiders traders include Paribas Securities Corp Bnp, Corinne Pankovcin, and Jeffrey W. Runge. On average, ADiTx Therapeutics executives and independent directors trade stock every 93 days with the average trade being worth of $2,473. The most recent stock trade was executed by Paribas Securities Corp Bnp on 6 September 2023, trading 20,800 units of ADTX stock currently worth $691,184.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
ADiTx Therapeutics executives and other stock owners filed with the SEC include: